Find information on thousands of medical conditions and prescription drugs.

Goserelin

Goserelin is an injectable gonadotropin releasing hormone agonist (GnRH agonist). It stops the production of sex hormones (testosterone and oestrogen) and is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction. more...

 Home
Diseases
Medicines
A
B
C
D
E
F
G
Gabapentin
Gabitril
Galantamine
Gamma-hydroxybutyrate
Ganciclovir
Garamycin
Gaviscon
Gemcitabine
Gemfibrozil
Gemhexal
Gemzar
Generlac
Gentamicin
Geodon
Gleevec
Gliadel
Gliadel Wafer
Glibenclamide
Glimepiride
Glipizide
Glucagon
Glucobay
Glucohexal
Glucophage
Glucosamine
Glucotrol
Glutethimide
Golytely
Gonadorelin
Goserelin
Gramicidin
Gramicidin S
Granisetron
Grifulvin V
Griseofulvin
Guaifenesin
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

It is available as a 1-month depot and a long-acting 3-month depot. Both depots are used for the treatment of prostate cancer, endometriosis and uterine fibroids but only the 1-month depot is approved for breast cancer, endometrial thinning and assisted reproduction.

Goserelin is marketed by AstraZeneca with the brand name Zoladex. It was first launched in 1987 and is currently the second-largest selling LHRHa in the world. It is currently available in more than one hundred markets.

Side effects

Goserelin causes an increase in bone pain and symptoms of prostatic cancer during the first few weeks of treatment. As your body adjusts to the medication, the symptoms will disappear. Goserelin may cause hot flashes, headache, stomach upset, difficulty urinating, weight gain, swelling and tenderness of breasts, decreased erections, reduced sexual desire.

Read more at Wikipedia.org
• [List your site here Free!]

Hormone Treatment Extends Pain-Free Interval
From OB/GYN News, 10/1/99 by Katherine Arnold

Goserelin depot injections lengthened the time to pelvic pain recurrence in women undergoing surgery for symptomatic endometriosis, reported Dr. Paolo Vercellini of the University of Milan and his colleagues.

The gonadotropin-releasing hormone did not delay the time to conception or lower the pregnancy rates in patients who wanted to have children.

In a randomized study, goserelin injections were given after surgery to 133 women a total of six times at 28-day intervals; 134 women serving as controls received no hormonal treatment. All patients were examined on a regular basis after surgery and evaluated for recurrence of dysmenorrhea, nonmenstrual pain, deep dyspareunia, or general discomfort (Br.J. Obstet. Gynaecol. 106[7]:672-77, 1999).

One year after surgery, 13.1% of the patients who received goserelin had moderate or severe symptoms, compared with 21.4% in the control group. At 2 years, 23.5% in the goserelin group and 36.5% in the control group had a recurrence of symptoms.

Neither the results at 1 year nor those at 2 years were statistically significant; however, the pain-free interval was significantly longer in the goserelin group than in the control group.

The study design was open label because of the frequent side effects of gonadotropin-releasing hormone treatment, the investigators reported.

COPYRIGHT 1999 International Medical News Group
COPYRIGHT 2004 Gale Group

Return to Goserelin
Home Contact Resources Exchange Links ebay